Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis

被引：0
|
作者：
Kappos, L.
Leppert, D.
Tinbergen, J.
Gerber, M.
Hauser, S. L.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：424 / 424
页数：1
相关论文
共 50 条
  • [31] Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia
    Bauer, Kathrin
    Rancea, Michaela
    Roloff, Verena
    Elter, Thomas
    Hallek, Michael
    Engert, Andreas
    Skoetz, Nicole
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (11):
  • [32] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis
    Zhong, Michael
    van der Walt, Anneke
    Campagna, Maria Pia
    Stankovich, Jim
    Butzkueven, Helmut
    Jokubaitis, Vilija
    [J]. NEUROTHERAPEUTICS, 2020, 17 (04) : 1768 - 1784
  • [33] Real-world evidence of anti-CD20 monoclonal antibodies in chilean patients with multiple sclerosis
    Del-Canto, A.
    Garcia, L.
    Aylwin, E.
    Jurgensen-Heinrich, L.
    Guzman-Carcamo, I.
    Gutierrez-Calquin, L.
    Barrera-Hormazabal, A.
    Cruz, J. P.
    Bravo-Grau, S.
    Pelayo, C.
    Soler, B.
    Uribe-San-Martin, R.
    Carcamo, C.
    Ciampi, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 383 - 384
  • [34] Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)
    Cooper, HL
    Healy, E
    Theaker, JM
    Friedmann, PS
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (04) : 366 - 368
  • [35] Anti-cd20 monoclonal antibody treatment (rituximab) in acute lymphoblastic leukemia
    Jándula, BM
    Nomdedeu, J
    Marín, P
    Muñoz, L
    Vivancos, P
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S92 - S92
  • [36] Treatment of posttransplantation diabetes mellitus with anti-CD20 monoclonal antibodies
    Vandenbosch, K
    Champagne, MA
    Gonthier, M
    Moghrabi, A
    Vachon, MF
    Duval, M
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 64 - 64
  • [37] Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)
    Dupuy, A
    Viguier, M
    Bédane, C
    Cordoliani, F
    Blaise, S
    Aucouturier, F
    Bonnetblanc, JM
    Morel, P
    Dubertret, L
    Bachelez, H
    [J]. ARCHIVES OF DERMATOLOGY, 2004, 140 (01) : 91 - 96
  • [38] Treatment of Cutaneous Lymphoid Hyperplasia with the Monoclonal Anti-CD20 Antibody Rituximab
    Martin, Stephanie J.
    Duvic, Madeleine
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (03): : 286 - 288
  • [39] Characterization of cytokine profiles in patients with multiple sclerosis under anti-CD20 therapy with ocrelizumab
    Koerner, Gudrun
    Gingele, Stefan
    Christina, Anna
    Pietschmann, Saparilla
    Konen, Franz Felix
    Jendretzky, Konstantin Fritz
    Schwenkenbecher, Philipp
    Hummert, Martin W.
    Jacobs, Roland
    Skripuletz, Thomas
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 231 - 232
  • [40] Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk - No
    Tallantyre, Emma C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (08) : 1175 - 1177
12345